SEC Form 4 · accession 0001144204-18-012823

ANI PHARMACEUTICALS INC · ANIP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Arthur Przybyl

Officer — President and CEO · Director

Period of report

Mar 1, 2018

Accepted (ET)

Mar 5, 2018 · 5:00 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001023024

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 1, 2018	M	9,375	$40.59	A	219,358	D
Common Stock	Mar 1, 2018	M	6,375	$33.00	A	225,733	D
Common Stock	Mar 1, 2018	M	8,236	$6.36	A	233,969	D
Common Stock^F1	Mar 1, 2018	S	11,326	$60.59	D	222,643	D
Common Stock^F2	Mar 1, 2018	S	8,400	$61.62	D	214,243	D
Common Stock^F3	Mar 1, 2018	S	4,260	$62.17	D	209,983	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option^F4	$40.59	Mar 1, 2018	M	9,375	D	—	Apr 6, 2026	Common Stock	9,375	28,125	D
Stock Option^F5	$33.00	Mar 1, 2018	M	6,375	D	—	Mar 31, 2024	Common Stock	6,375	6,375	D
Stock Option^F6	$6.36	Mar 1, 2018	M	8,236	D	—	Jul 11, 2023	Common Stock	8,236	15,723	D

Explanation of responses

F1This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2This transaction was executed in multiple trades at prices ranging from $61.00 to $61.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $62.00 to $62.525. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 7, 2016.
F5The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 1, 2014.
F6The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013.